Abstract
Highlights
Despite the common practice of switching patients from one medicine to another—to improve efficacy, safety, or tolerability—guidance on how to do so is uncommon. During this time of global shortage of glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) ± glucose‐dependent insulinotropic polypeptide (GIP) RA therapies, this research letter offers a quick clinical reference of rough equivalency between GLP‐1 ± GIP RA for A1c and body weight reduction in people with type 2 diabetes.
Keywords:
GIP/GLP‐1; GLP‐1; switching GLP‐1 RA.
MeSH terms
-
Blood Glucose / analysis
-
Blood Glucose / metabolism
-
Diabetes Mellitus, Type 2* / blood
-
Diabetes Mellitus, Type 2* / drug therapy
-
Glucagon-Like Peptide 1* / agonists
-
Glycated Hemoglobin* / analysis
-
Glycated Hemoglobin* / metabolism
-
Humans
-
Hypoglycemic Agents* / therapeutic use
-
Receptors, Gastrointestinal Hormone* / agonists
-
Weight Loss* / drug effects
Substances
-
Glucagon-Like Peptide 1
-
Hypoglycemic Agents
-
Glycated Hemoglobin
-
Receptors, Gastrointestinal Hormone
-
gastric inhibitory polypeptide receptor
-
hemoglobin A1c protein, human
-
Blood Glucose